Get the Stockscreener App
4.51
4.75%
-0.225
After Hours:
4.50
-0.010
-0.22%
Aquestive Therapeutics Inc stock is traded at $4.51, with a volume of 1.26M.
It is down -4.75% in the last 24 hours and down -8.89% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.735
Open:
$4.69
24h Volume:
1.26M
Relative Volume:
0.96
Market Cap:
$421.24M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.02
EPS:
-0.45
Net Cash Flow:
$-24.91M
1W Performance:
-1.31%
1M Performance:
-8.89%
6M Performance:
+41.82%
1Y Performance:
+132.47%
1-Day Range:
$4.44
$4.69
1-Week Range:
$4.36
$4.88
52-Week Range:
$1.84
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AQST | 4.51 | 421.24M | 58.36M | -25.72M | -24.91M | -0.45 |
| ZTS | 176.71 | 79.55B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.55 | 43.18B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.33 | 42.26B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.08 | 19.35B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc - GuruFocus.com
Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Aquestive Therapeutics to Present at Jefferies and Piper Sandler Healthcare Conferences | AQST Stock News - StockTitan
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
(AQST) On The My Stocks Page - Stock Traders Daily
HC Wainwright Issues Pessimistic Estimate for AQST Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for AQST Earnings - MarketBeat
Aquestive Therapeutics announces board changes - Investing.com India
Aquestive Therapeutics announces board changes By Investing.com - Investing.com UK
Aquestive Therapeutics Advances Drug Candidates Amid Challenges - TipRanks
Lake Street lifts Aquestive stock target, keeps buy on NDA submission - Investing.com UK
Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from HC Wainwright - MarketBeat
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Aquestive Therapeutics: Progress in Drug Innovation - TipRanks
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates - MSN
Aquestive: Rare Opportunity With Dual Platform Strategy (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Aquestive Therapeutics: Q3 Earnings Snapshot - mySA
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics reports Q3 EPS (13c), consensus (13c) - TipRanks
AQSTAquestive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aquestive Therapeutics Optimistic Financial and Strategic Outlook - TipRanks
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need T - GuruFocus.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Consensus Target Price from Brokerages - MarketBeat
Learn to Evaluate (AQST) using the Charts - Stock Traders Daily
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $13.00 - Defense World
Aquestive Therapeutics (AQST) Set to Announce Quarterly Earnings on Monday - MarketBeat
Leerink raises Aquestive Therapeutics stock PT on 'top-line' study results - Investing.com Canada
Aquestive Therapeutics to Present Subsequent Analysis of - GlobeNewswire
Leerink Partners Raises Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00 - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study - Yahoo Finance
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American - GlobeNewswire
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$51m last week but individual investors profited the most - Simply Wall St
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission - Investing.com Australia
Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success - Barchart
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc (AQST) Has Recovered 74.67% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Aquestive Therapeutics Announces Positive Topline Results - GlobeNewswire
Aquestive Therapeutics a new overweight at Piper on oral film products - MSN
Aquestive Therapeutics to Report Third Quarter 2024 - GlobeNewswire
Aquestive Therapeutics updates bylaws, shortens nomination look-back By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schobel Alexander Mark | Chief Innovation/Tech Officer |
Mar 08 '24 |
Sale |
5.19 |
25,000 |
129,685 |
1,040,371 |
1.01%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):